OPKO Health (OPK) Misses Q1 EPS by 18c, Revenue Beats

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to OPKO Health (OPK) Misses Q1 EPS by 18c, Revenue Beats

OPKO Announces First Quarter Operating and Financial Results

May 11, 2015 4:00 PM EDT

Pfizer Collaboration Agreement for Long Acting Human Growth Hormone Closed in January 2015; OPKO Received $295 million of $570 Million Total Potential Pre-Commercialization Payments Acquired EirGen Pharma, A Growing, Profitable Specialty Pharmaceutical Developer and Manufacturer RayaldeeTM New Drug Application (NDA) Submission Expected Later in May; Positive Rayaldee Phase 3 Clinical Trial Results Presented at the National Kidney Foundation Spring Clinical Meetings and 2015 ENDO Conference Investigational New Drug (IND) Application for Long Acting Factor VIIa-CTP for Hemophilia Accepted in Q1 2015; Phase 2a Clinical Trial to Commence in 1H 2015... More